Pembrolizumab in Treating Patients With Malignant Mesothelioma

Summary

This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum). Monoclonal antibodies, such as pembrolizumab, work by blocking a protein called programmed cell death 1 (PD-1) which may stimulate an immune response and kill tumor cells.

Timeline

Start

2015-03-31

Primary completion

2024-08-13

Completion

2026-03-20

Drugs

Indications